Medical Oncology
Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.
Recent Discussions
Does your evaluation of a young person with spontaneous upper extremity DVT vary as compared to lower extremity DVT?
The workup for a young adult with an upper extremity DVT differs for me in two ways: Venous thoracic outlet syndrome must be suspected and a careful history of repetitive overhead movements must be obtained. Consulting your vascular surgery team in these cases to ensure the anatomy does not put the...
Is there a role for reirradiation for SCC oral tongue with high-risk features (i.e., PNI, close margins) following surgery?
Consider in patients with ENE, positive margins, deeply infiltrative tumors (>1 cm), or T4. Avoid if <6 mo from prior RT, ongoing wound healing issues in target, or pre-existing severe toxicity (e.g., ORN, severe fibrosis), though this is conditional.
Which PARP inhibitor do you recommend for maintenance therapy in BRCA mutated ovarian cancer after primary chemotherapy and why?
Given the abundance of both efficacy and safety data available for Olaparib in this setting, I use Olaparib for maintenance therapy in BRCA+ ovarian cancer patients after primary chemotherapy. The 5-year PFS data from SOLO-1, confirming sustained benefit beyond the end of treatment, further speaks t...
Would you offer surgery for an MSI-H pancreatic adenocarcinoma who had deep response to pembrolizumab?
This is a hard question. The 19-9 gives me pause (even with normalization) and I think most likely I would push on with checkpoint inhibitor therapy for a total of two years given that it is very unlikely surgery will clear disease and ICI may get you to a durable complete response on its own. I don...
In an elderly transplant ineligible IDH1-mutated patient with AML, who is in remission after 6 cycles of azacitidine and ivosidenib, would you discontinue azacitidine after cycle 6 and continue maintenance ivosidenib until progression/toxicity or continue both azacitidine and ivosidenib?
Our practice is to typically continue azacitidine + ivosidenib per the AGILE study (Montesinos et al., PMID 35443108) as long as the patient is not having excessive myelosuppression/toxicity and doesn't feel strongly about coming off azacitidine. That being said, there are data to support ivosidenib...
In an elderly transplant ineligible IDH1-mutated patient with AML, who is in remission after 6 cycles of azacitidine and ivosidenib, would you discontinue azacitidine after cycle 6 and continue maintenance ivosidenib until progression/toxicity or continue both azacitidine and ivosidenib?
Our practice is to typically continue azacitidine + ivosidenib per the AGILE study (Montesinos et al., PMID 35443108) as long as the patient is not having excessive myelosuppression/toxicity and doesn't feel strongly about coming off azacitidine. That being said, there are data to support ivosidenib...
Do you recommend postoperative radiation for spinal cord compression DLBCL?
I would recommend postoperative RT, following completion of systemic therapy. I would restage with PET-CT prior to RT. If CR: 30 Gy would suffice.
How do you counsel patients who experience diarrhea from mycophenolate mofetil (Cellcept)?
I have them stop the drug, and when their bowels are back to normal (usually just a couple of days), I resume with 1 tablet bid of mycophenolate mofetil (MMF, CellCept), then a few days later go up to 1 tab tid, a few days later 2 tabs bid... etc. I instruct them to go down to the most recent dose ...
How would you approach management of a patient with ESRD on the transplant list who is found to have high titer APS labs (ACL, B2GP1, LAC)?
This is an excellent but rather complex question. Management of patients with ESRD on the transplant list who are found to have high titer APS labs (ACL, B2GP1, LAC) depend on the renal histology, underlying autoimmune disease history, and comorbidities. Patients with thrombotic manifestations resul...
Would you recommend post operative radiation in an adult patient with a thoracic spine osteosarcoma?
The following answer is extrapolated from AOST2032 which is a pediatric clinical trial but is relevant to the question at hand. This case touches upon the concepts outlined in the AOST2032 research protocol for osteosarcoma radiation therapy. While acknowledging this is just one protocol and not a ...